Overview

First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

Status:
Active, not recruiting
Trial end date:
2021-08-30
Target enrollment:
Participant gender:
Summary
Phase 1a/1b Trial to evaluate the tolerability and safety of IBI101 monotherapy or in combination with Sintilimab in advanced solid tumor patients.
Phase:
Phase 1
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.